Siga Technologies Inc. $SIGA Shares Acquired by LSV Asset Management

LSV Asset Management lifted its stake in shares of Siga Technologies Inc. (NASDAQ:SIGA) by 28.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 538,630 shares of the company’s stock after acquiring an additional 120,300 shares during the quarter. LSV Asset Management owned about 0.75% of Siga Technologies worth $3,291,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in SIGA. Arrowstreet Capital Limited Partnership increased its stake in shares of Siga Technologies by 44.2% during the third quarter. Arrowstreet Capital Limited Partnership now owns 834,683 shares of the company’s stock valued at $7,637,000 after acquiring an additional 255,902 shares during the period. Bank of America Corp DE increased its stake in shares of Siga Technologies by 143.2% during the second quarter. Bank of America Corp DE now owns 405,730 shares of the company’s stock valued at $2,645,000 after acquiring an additional 238,869 shares during the period. CSM Advisors LLC increased its stake in shares of Siga Technologies by 66.5% during the third quarter. CSM Advisors LLC now owns 596,512 shares of the company’s stock valued at $5,458,000 after acquiring an additional 238,255 shares during the period. Millennium Management LLC increased its stake in shares of Siga Technologies by 353.8% during the third quarter. Millennium Management LLC now owns 256,337 shares of the company’s stock valued at $2,345,000 after acquiring an additional 199,852 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in shares of Siga Technologies by 744.6% during the third quarter. JPMorgan Chase & Co. now owns 211,055 shares of the company’s stock valued at $1,931,000 after acquiring an additional 186,067 shares during the period. Institutional investors and hedge funds own 55.40% of the company’s stock.

Siga Technologies Stock Performance

Shares of NASDAQ:SIGA opened at $4.67 on Wednesday. The stock has a market capitalization of $334.93 million, a price-to-earnings ratio of 17.30 and a beta of 0.93. Siga Technologies Inc. has a 1-year low of $4.09 and a 1-year high of $9.62. The company has a 50 day moving average price of $4.73 and a 200 day moving average price of $5.80.

Siga Technologies (NASDAQ:SIGA) last issued its earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share for the quarter. The business had revenue of $6.24 million for the quarter. Siga Technologies had a return on equity of 10.60% and a net margin of 21.58%.

Siga Technologies Dividend Announcement

The company also recently disclosed a special dividend, which was paid on Thursday, April 23rd. Shareholders of record on Tuesday, April 7th were given a dividend of $0.60 per share. The ex-dividend date was Tuesday, April 7th.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of Siga Technologies from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 11th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the company presently has a consensus rating of “Hold”.

Siga Technologies Profile

Siga Technologies, Inc (NASDAQ: SIGA) is a specialty pharmaceutical company focused on the development, manufacturing and commercialization of medical countermeasures for public health emergencies and biological threats. The company’s flagship product, TPOXX® (tecovirimat), is the first and only antiviral approved by the U.S. Food and Drug Administration for the treatment of smallpox. Siga has entered into procurement and development contracts with U.S. government agencies, including the Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense, to supply TPOXX® for the Strategic National Stockpile.

Founded in 2002, Siga has built a pipeline of therapies targeting high-consequence pathogens such as smallpox, plague and other potential biothreat agents.